Analytical Data
-
基因名
Kras4B
- Application
-
别名
K-Ras 2Ki-Rasc-K-rasc-Ki-ras
-
种属
Human
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01116
-
表达区间
2-168aa
-
分子量
23.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Kras4B is a member of the Ras family of proteins, which play crucial roles in cellular signaling pathways that regulate cell proliferation, survival, and differentiation. Mutations in the KRAS gene are implicated in a variety of cancers, particularly pancreatic, colorectal, and lung cancers, making it a significant target for therapeutic intervention. The Kras4B isoform, specifically, has garnered attention due to its frequent mutations that lead to constitutive activation, promoting oncogenic signaling pathways. Research into Kras4B has focused on understanding its structure, function, and the molecular mechanisms by which it contributes to tumorigenesis. This includes efforts to explore its interactions with downstream effectors and regulatory proteins. Moreover, the development of inhibitors targeting mutated Kras4B remains a critical area of investigation, aiming to provide new treatment options for patients with KRAS-driven malignancies. Insights gained from studying Kras4B are not only vital for cancer biology but also hold promise for advancing precision medicine strategies that could improve patient outcomes in KRAS-associated cancers.
